Investigational PARP inhibitor promising in BRCA-related cancers
Tuesday, October 22, 2013 - 11:30
in Health & Medicine
An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results.